Cellply srl has obtained a grant by the European Commission to support its R&D program
May 2018 — Cellply has obtained a grant by the European Commission to support its R&D program. It is the largest one among the nine Italian companies funded in the last SME Instrument call and one of the largest at EU level since the start of the SME Instrument program in 2014. This will provide the resources to complete the development of an innovative diagnostic platform.
Cellply, based in Bologna, Italy, was founded in 2013 by two engineers, Professor Roberto Guerrieri from the University of Bologna and Massimo Bocchi. It is a medtech start-up company specialized in in vitro diagnostic systems aiming at supporting personalized oncology treatments. In 2014, the company started the development of an in vitro diagnostic platform which enabled the isolation of a tiny amount of live tumor cells sampled from patients within 20,000 microwells and to analyze the action of multiple drugs in parallel by means of proprietary algorithms to predict the response of the patient to candidate drug therapies.
Our role in the transaction
Oaklins' team in Italy successfully assisted Cellply along the entire fundraising process.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more